There are ongoing clinical trials that aim to establish the efficiency of the dual blockade of the TIGIT/CD155/DNAM-1 and PD-1/PD-L1 pathways in the treatment of such tumors as OC, esophageal cancer, and non-small-cell lung cancer [134]. Here, CD226 is linked to non-small cell lung carcinoma.